2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06C.02 Clinical Features and Survival Outcome of Lung Invasive Mucinous Adenocarcinoma: A Real-World Analysis of 387,197 Patients

EP.06C.02 Clinical Features and Survival Outcome of Lung Invasive Mucinous Adenocarcinoma: A Real-World Analysis of 387,197 Patients

Back to course

Pdf Summary

The study titled "Clinical characteristics and survival outcome of lung invasive mucinous adenocarcinoma: a real-world analysis of 387,197 patients" conducted by Yu Jung Heo and colleagues analyzes the unique clinical characteristics and prognostic factors of pulmonary invasive mucinous adenocarcinoma (IMA) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Spanning from 2000 to 2021, the analysis included both IMA and non-IMA cases derived from 17 SEER registries. <br /><br />Through the use of Kaplan-Meier curves and propensity score matching (PSM) to control confounding variables like age, gender, race, and treatment modalities (surgery, chemotherapy, radiation), the study focused on 22,706 patients for detailed evaluation. The findings reveal that IMA has a higher prevalence among females and white individuals. Patients with advanced-stage IMA had poorer outcomes compared to those with non-IMA, especially in Stage IV cases treated with chemotherapy, where IMA patients showed less benefit.<br /><br />Overall survival (OS) comparisons indicated different outcomes based on cancer stages, with statistically significant differences highlighting the generally poorer prognosis for advanced stage IMA. Univariate and multivariate Cox-proportional hazard regression analyses quantified the survival risks associated with various factors. <br /><br />Conclusions from the study suggest while IMA shows comparatively better clinical outcomes than non-IMA at early stages, the disease exhibits less favorable results as it progresses to advanced stages. Furthermore, the benefit derived from chemotherapy in IMA cases is noticeably lower compared to non-IMA, suggesting potential differences in treatment response that could guide therapeutic strategies.<br /><br />This study provides new insights into the behavior and treatment outcomes of IMA, potentially influencing clinical decisions for managing this subtype of lung cancer.

Asset Subtitle

Wongi Woo

Meta Tag

Speaker Wongi Woo

Topic Pathology and Biomarkers

Keywords

lung invasive mucinous adenocarcinoma

clinical characteristics

survival outcome

SEER database

Kaplan-Meier curves

propensity score matching

advanced-stage IMA

chemotherapy response

prognostic factors

therapeutic strategies